Kayla E Hanson1, Kristin Goddard2, Ned Lewis2, Bruce Fireman2, Tanya R Myers3, Nandini Bakshi4, Eric Weintraub3, James G Donahue1, Jennifer C Nelson5, Stan Xu6, Jason M Glanz7, Joshua T B Williams8, Jonathan D Alpern9, Nicola P Klein2. 1. Marshfield Clinic Research Institute, Marshfield, Wisconsin. 2. Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California, Oakland, California. 3. Immunization Safety Office, Centers for Disease Control and Prevention, Atlanta, Georgia. 4. The Permanente Medical Group, Oakland, California. 5. Kaiser Permanente Washington Health Research Institute, Seattle, Washington. 6. Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California. 7. Kaiser Permanente Colorado Institute for Health Research, Denver, Colorado. 8. Ambulatory Care Services, Denver Health & Hospital Authority, Denver, Colorado. 9. HealthPartners Institute, Minneapolis, Minnesota.
Abstract
Importance: Postauthorization monitoring of vaccines in a large population may detect rare adverse events not identified in clinical trials such as Guillain-Barré syndrome (GBS), which has a background rate of 1 to 2 per 100 000 person-years. Objective: To describe cases and incidence of GBS following COVID-19 vaccination and assess the risk of GBS after vaccination for Ad.26.COV2.S (Janssen) and mRNA vaccines. Design, Setting, and Participants: This cohort study used surveillance data from the Vaccine Safety Datalink at 8 participating integrated health care systems in the United States. There were 10 158 003 participants aged at least 12 years. Data analysis was performed from November 2021 to February 2022. Exposures: Ad.26.COV2.S, BNT162b2 (Pfizer-BioNTech), or mRNA-1273 (Moderna) COVID-19 vaccine, including mRNA vaccine doses 1 and 2, December 13, 2020, to November 13, 2021. Main Outcomes and Measures: GBS with symptom onset in the 1 to 84 days after vaccination, confirmed by medical record review and adjudication. Descriptive characteristics of confirmed cases, GBS incidence rates during postvaccination risk intervals after each type of vaccine compared with the background rate, rate ratios (RRs) comparing GBS incidence in the 1 to 21 vs 22 to 42 days postvaccination, and RRs directly comparing risk of GBS after Ad.26.COV2.S vs mRNA vaccination, using Poisson regression adjusted for age, sex, race and ethnicity, site, and calendar day. Results: From December 13, 2020, through November 13, 2021, 15 120 073 doses of COVID-19 vaccines were administered to 7 894 989 individuals (mean [SE] age, 46.5 [0.02] years; 8 138 318 doses received [53.8%] by female individuals; 3 671 199 doses received [24.3%] by Hispanic or Latino individuals, 2 215 064 doses received [14.7%] by Asian individuals, 6 266 424 doses received [41.4%] by White individuals), including 483 053 Ad.26.COV2.S doses, 8 806 595 BNT162b2 doses, and 5 830 425 mRNA-1273 doses. Eleven cases of GBS after Ad.26.COV2.S were confirmed. The unadjusted incidence rate of GBS per 100 000 person-years in the 1 to 21 days after Ad.26.COV2.S was 32.4 (95% CI, 14.8-61.5), significantly higher than the background rate, and the adjusted RR in the 1 to 21 vs 22 to 42 days following Ad.26.COV2.S was 6.03 (95% CI, 0.79-147.79). Thirty-six cases of GBS after mRNA vaccines were confirmed. The unadjusted incidence rate per 100 000 person-years in the 1 to 21 days after mRNA vaccines was 1.3 (95% CI, 0.7-2.4) and the adjusted RR in the 1 to 21 vs 22 to 42 days following mRNA vaccines was 0.56 (95% CI, 0.21-1.48). In a head-to-head comparison of Ad.26.COV2.S vs mRNA vaccines, the adjusted RR was 20.56 (95% CI, 6.94-64.66). Conclusions and Relevance: In this cohort study of COVID-19 vaccines, the incidence of GBS was elevated after receiving the Ad.26.COV2.S vaccine. Surveillance is ongoing.
Importance: Postauthorization monitoring of vaccines in a large population may detect rare adverse events not identified in clinical trials such as Guillain-Barré syndrome (GBS), which has a background rate of 1 to 2 per 100 000 person-years. Objective: To describe cases and incidence of GBS following COVID-19 vaccination and assess the risk of GBS after vaccination for Ad.26.COV2.S (Janssen) and mRNA vaccines. Design, Setting, and Participants: This cohort study used surveillance data from the Vaccine Safety Datalink at 8 participating integrated health care systems in the United States. There were 10 158 003 participants aged at least 12 years. Data analysis was performed from November 2021 to February 2022. Exposures: Ad.26.COV2.S, BNT162b2 (Pfizer-BioNTech), or mRNA-1273 (Moderna) COVID-19 vaccine, including mRNA vaccine doses 1 and 2, December 13, 2020, to November 13, 2021. Main Outcomes and Measures: GBS with symptom onset in the 1 to 84 days after vaccination, confirmed by medical record review and adjudication. Descriptive characteristics of confirmed cases, GBS incidence rates during postvaccination risk intervals after each type of vaccine compared with the background rate, rate ratios (RRs) comparing GBS incidence in the 1 to 21 vs 22 to 42 days postvaccination, and RRs directly comparing risk of GBS after Ad.26.COV2.S vs mRNA vaccination, using Poisson regression adjusted for age, sex, race and ethnicity, site, and calendar day. Results: From December 13, 2020, through November 13, 2021, 15 120 073 doses of COVID-19 vaccines were administered to 7 894 989 individuals (mean [SE] age, 46.5 [0.02] years; 8 138 318 doses received [53.8%] by female individuals; 3 671 199 doses received [24.3%] by Hispanic or Latino individuals, 2 215 064 doses received [14.7%] by Asian individuals, 6 266 424 doses received [41.4%] by White individuals), including 483 053 Ad.26.COV2.S doses, 8 806 595 BNT162b2 doses, and 5 830 425 mRNA-1273 doses. Eleven cases of GBS after Ad.26.COV2.S were confirmed. The unadjusted incidence rate of GBS per 100 000 person-years in the 1 to 21 days after Ad.26.COV2.S was 32.4 (95% CI, 14.8-61.5), significantly higher than the background rate, and the adjusted RR in the 1 to 21 vs 22 to 42 days following Ad.26.COV2.S was 6.03 (95% CI, 0.79-147.79). Thirty-six cases of GBS after mRNA vaccines were confirmed. The unadjusted incidence rate per 100 000 person-years in the 1 to 21 days after mRNA vaccines was 1.3 (95% CI, 0.7-2.4) and the adjusted RR in the 1 to 21 vs 22 to 42 days following mRNA vaccines was 0.56 (95% CI, 0.21-1.48). In a head-to-head comparison of Ad.26.COV2.S vs mRNA vaccines, the adjusted RR was 20.56 (95% CI, 6.94-64.66). Conclusions and Relevance: In this cohort study of COVID-19 vaccines, the incidence of GBS was elevated after receiving the Ad.26.COV2.S vaccine. Surveillance is ongoing.
Authors: James J Sejvar; Katrin S Kohl; Jane Gidudu; Anthony Amato; Nandini Bakshi; Roger Baxter; Dale R Burwen; David R Cornblath; Jan Cleerbout; Kathryn M Edwards; Ulrich Heininger; Richard Hughes; Najwa Khuri-Bulos; Rudolf Korinthenberg; Barbara J Law; Ursula Munro; Helena C Maltezou; Patricia Nell; James Oleske; Robert Sparks; Priscilla Velentgas; Patricia Vermeer; Max Wiznitzer Journal: Vaccine Date: 2010-06-18 Impact factor: 3.641
Authors: Grace M Lee; Sharon K Greene; Eric S Weintraub; James Baggs; Martin Kulldorff; Bruce H Fireman; Roger Baxter; Steven J Jacobsen; Stephanie Irving; Matthew F Daley; Ruihua Yin; Allison Naleway; James D Nordin; Lingling Li; Natalie McCarthy; Claudia Vellozzi; Frank Destefano; Tracy A Lieu Journal: Am J Prev Med Date: 2011-08 Impact factor: 5.043
Authors: Irene M Shui; Melisa D Rett; Eric Weintraub; Michael Marcy; Anthony A Amato; Sarah I Sheikh; Doreen Ho; Grace M Lee; W Katherine Yih Journal: Neuroepidemiology Date: 2012-07-28 Impact factor: 3.282
Authors: Jessica R MacNeil; John R Su; Karen R Broder; Alice Y Guh; Julia W Gargano; Megan Wallace; Stephen C Hadler; Heather M Scobie; Amy E Blain; Danielle Moulia; Matthew F Daley; Veronica V McNally; José R Romero; H Keipp Talbot; Grace M Lee; Beth P Bell; Sara E Oliver Journal: MMWR Morb Mortal Wkly Rep Date: 2021-04-30 Impact factor: 17.586
Authors: Sara E Oliver; Julia W Gargano; Heather Scobie; Megan Wallace; Stephen C Hadler; Jessica Leung; Amy E Blain; Nancy McClung; Doug Campos-Outcalt; Rebecca L Morgan; Sarah Mbaeyi; Jessica MacNeil; José R Romero; H Keipp Talbot; Grace M Lee; Beth P Bell; Kathleen Dooling Journal: MMWR Morb Mortal Wkly Rep Date: 2021-03-05 Impact factor: 17.586
Authors: Holly C Groom; Bradley Crane; Allison L Naleway; Eric Weintraub; Matthew F Daley; Kris Wain; Mary Beth Kurilo; Rachael Burganowski; Malini B DeSilva; James G Donahue; Sungching C Glenn; Kristin Goddard; Michael L Jackson; Elyse O Kharbanda; Ned Lewis; Yingbo Lou; Marlene Lugg; Erica Scotty; Lina S Sy; Joshua T B Williams; Stephanie A Irving Journal: Vaccine Date: 2021-12-31 Impact factor: 3.641
Authors: Chongliang Luo; Jingcheng Du; Adam Cuker; Ebbing Lautenbach; David A Asch; Gregory A Poland; Cui Tao; Yong Chen Journal: Sci Rep Date: 2022-06-29 Impact factor: 4.996
Authors: Amir J Khan; Ala Szczepura; Shea Palmer; Chris Bark; Catriona Neville; David Thomson; Helen Martin; Charles Nduka Journal: Clin Rehabil Date: 2022-07-05 Impact factor: 2.884
Authors: Luigi Cari; Mahdieh Naghavi Alhosseini; Alberta Bergamo; Sabrina Pacor; Sabata Pierno; Gianni Sava; Giuseppe Nocentini Journal: Front Cardiovasc Med Date: 2022-09-29